Solid Biosciences to Participate at Chardan’s 8th Annual Genetic Medicines Conference

Rhea-AI Summary

Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on developing precision genetic medicines for neuromuscular and cardiac diseases, has announced its participation in Chardan's 8th Annual Genetic Medicines Conference. The event will feature a fireside chat with Bo Cumbo, President and CEO, and Dr. Gabriel Brooks, Chief Medical Officer, scheduled for Monday, September 30, 2024, at 11:00 am ET.

Interested parties can access a live webcast of the fireside chat through the Events page of the Investors section on Solid Biosciences' website. A replay of the webcast will be available for 30 days after the event. Institutional investors wishing to meet with the management team during the conference are advised to contact their Chardan representatives.

CHARLESTOWN, Mass., Sept. 23, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that Bo Cumbo, President and CEO, and Gabriel Brooks, M.D., Chief Medical Officer, will participate in a fireside chat at Chardan’s 8^th Annual Genetic Medicines Conference on Monday, September 30, 2024, at 11:00 am ET.

A live webcast of the fireside chat will be available on the Events page of the Investors section of the Company website or by clicking here. A webcast replay will be archived for 30 days on the Events page.

Institutional investors interested in meeting with management during the conferences may reach out to their Chardan representatives.

About Solid Biosciences
Solid Biosciences is a precision genetic medicine company focused on advancing a portfolio of gene therapy candidates including SGT-003 for the treatment of Duchenne muscular dystrophy (Duchenne), SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia (CPVT), AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy, and additional assets for the treatment of fatal cardiac diseases. Solid is advancing its diverse pipeline across rare neuromuscular and cardiac diseases, bringing together experts in science, technology, disease management, and care. Patient-focused and founded by those directly impacted, Solid’s mandate is to improve the daily lives of patients living with these devastating diseases. For more information, please visit www.solidbio.com.

Solid Biosciences Investor Contact:
Nicole Anderson
Director, Investor Relations and Corporate Communications
Solid Biosciences Inc.
investors@solidbio.com

Media Contact:
Glenn Silver
FINN Partners
glenn.silver@finnpartners.com

FAQ

When is Solid Biosciences (SLDB) participating in Chardan's Genetic Medicines Conference?

Solid Biosciences (SLDB) is participating in Chardan's 8th Annual Genetic Medicines Conference on Monday, September 30, 2024, at 11:00 am ET.

Who will represent Solid Biosciences (SLDB) at the Chardan conference?

Bo Cumbo, President and CEO, and Dr. Gabriel Brooks, Chief Medical Officer, will represent Solid Biosciences (SLDB) in a fireside chat at the Chardan conference.

How can investors access the Solid Biosciences (SLDB) fireside chat at the Chardan conference?

Investors can access a live webcast of the Solid Biosciences (SLDB) fireside chat through the Events page of the Investors section on the company's website.

What type of medicines does Solid Biosciences (SLDB) develop?

Solid Biosciences (SLDB) develops precision genetic medicines for neuromuscular and cardiac diseases.

How long will the webcast replay of Solid Biosciences' (SLDB) fireside chat be available?

The webcast replay of Solid Biosciences' (SLDB) fireside chat will be archived for 30 days on the Events page of the company's website.